AI-driven tool shows to improve risk stratification in colorectal cancer
A system integrating computer tomography scans and pathological markers offers promise to personalise adjuvant therapy
Data show that mirvetuximab soravtansine-gynx improves outcomes regardless of HRD status
Final analyses of the PICCOLO trial confirm the efficacy of the antibody–drug conjugate in recurrent platinum-sensitive ovarian cancer
Atezolizumab added to chemotherapy and bevacizumab is effective regardless of PD-L1 status in untreated recurrent and metastatic cervical cancer
An analysis of the BEATcc trial showed that PD-L1 is not a robust biomarker for response to treatment
Relacorilant added to nab-paclitaxel prolongs progression-free survival in platinum-resistant ovarian cancer
The ROSELLA trial highlights the efficacy and tolerability of the combination even in patients with a poorer prognosis
An analysis reveals distinct patterns of expression of antibody–drug conjugate targets in high-grade serous ovarian cancer
A small Japanese study provides useful insights on determining the role of these agents in cancer care, but studies in larger, more diverse populations are needed
Experts recommend limiting germline genetic testing for breast cancer to seven genes
Newly-released ESMO recommendations critically assess specific germline pathogenic variants in terms of cancer-related mortality and testing implications for patients and their families
AI integration in breast cancer – a long way ahead?
Experts’ discussions during ESMO Breast 2025 provided an overview on promises and challenges in the field
Will voice-enabled AI have a role in oncology?
Progress in artificial intelligence tools is opening-up novel modalities to provide education and doctor-patient communication
Study findings support a growing shift towards “personalised de-escalation” treatment strategies in anal and rectal cancer care
Reduced-dose chemoradiotherapy and non-surgical strategies show promising outcomes with fewer long-term side-effects in lower gastrointestinal cancers
Tucatinib combo continues to show durable benefit in HER2-mutated metastatic breast cancer
Final data from the SGNTUC-019 trial support the use of the agent with trastuzumab in heavily pretreated patients